Combination Therapies Development for Leukemia
Alfa Cytology specializes in the development of personalized and innovative combination therapies designed specifically for different subtypes of leukemia. The primary objective behind the development of combination therapies is to minimize the emergence of drug-resistant tumor cells. By combining treatment modalities with distinct mechanisms of action, these therapies aim to reduce drug resistance and effectively target a higher proportion of tumor cells.
Rationale for Combination Therapy in Leukemia
The combination of Ibrutinib and CAR-T cells is a potential option for CLL patients with poor prognosis. Ibrutinib's off-target effect on ITK can shift T cells towards a Th1 cytokine profile, favoring the proliferation and maintenance of chimeric receptor-expressing T cell populations. This immune response redirection may enhance therapeutic outcomes.
Fig. 1. Rationale for ibrutinib combination with cell therapy. (Deore, A.B. et al., 2019)
Combination therapies play a crucial role in evaluating novel therapeutic approaches, unlocking their complete potential, and determining optimal clinical strategies moving forward. Our services encompass the development of various combination therapies, utilizing 2D and 3D cell analysis, leukemia modeling, and screening platforms. We offer a wide range of services tailored to the development of combination therapies and beyond.
- Targeted Therapy and Chemotherapy
- Monoclonal Antibody and Targeted Therapy
- Immunotherapy and Cell Therapy
- Chemoimmunotherapy and Other Targeted Therapy
Combination Therapies for Different Types of Leukemia
Given the diversity in therapeutic drugs for different types of leukemia, we offer tailored services for your combination therapy development projects. Our comprehensive range of drug combinations encompasses but is not limited to the following examples.
Combination Therapies for Acute Myeloid Leukemia
There are thousands of drug combinations to explore for combination therapy. Utilizing computational models, we can recommend potential synergistic drug combinations, saving you time in preliminary research and aiding in the development of potential therapies for AML treatment.
- Venetoclax, HMA
- Venetoclax, LDAC
- Venetoclax, MCL1 inhibitors
- FLT3 inhibitors, Palbociclib
- IDH inhibitors, Chemotherapy drug
- Venetoclax, HMA, CD123 ADC
Combination Therapies for Acute Lymphoblastic Leukemia
Our services focus on the development of diverse treatment approaches, including combinations of chemotherapy, targeted therapies, immunotherapy, and hematopoietic stem cell transplantation.
- Asparaginase, Venetoclax
- CD19-directed CAR T-cell therapy, PD-1 inhibitors
- Blinatumomab, Bcr-Abl inhibitors
- CD19 antibody, Inotuzumab
Combination Therapies for Chronic Myeloid Leukemia
Through dosage testing and adjustment of the drug combination regimen, we assess their potential additive or synergistic effects in treating CML.
- Asciminib, Interferon
- Classic antineoplastic agents, Imatinib
- PD-L1 inhibitor, Dasatinib
Combination Therapies for Chronic Lymphocytic Leukemia
We specialize in the development of combination therapies involving different inhibitors, further optimizing treatment outcomes.
- Ibrutinib, Venetoclax
- Acalabrutinib, Venetoclax, Monoclonal antibody
- Venetoclax, BTK inhibitor
- Venetoclax, Anti-CD20 antibody
Contact Us
If you are seeking a collaborative partner in the development of combination therapies for leukemia, please contact our team. Together, Alfa Cytology can advance the field of leukemia treatment and provide better therapeutic options for patients.
Reference
- Timofeeva, N.; Gandhi, V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer Journal. 2021, 11(4): 79.